Junshi Biotech announced the completion of the first patient administration in the phase III clinical trial of JS203 combined chemotherapy for diffuse large B-cell lymphoma.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.